1
项与 124-iodine-labeled PSCA targeting minibody(University of California, Los Angeles) 相关的临床试验A Phase I Open Label Study to Evaluate the Tumor-targeting Properties and Safety of 124I-A11 PSCA Minibody in Patients With Metastatic Prostate, Bladder and Pancreatic Cancer.
The purpose of the study is to determine whether positron emission tomography (PET), using the new imaging drug [124 I] PSCA-Minibody can be used for imaging prostate, pancreatic or bladder cancer that has spread to the bones and soft tissues (e.g., lymph nodes, lungs, etc.). The PET imaging drug tested in this study binds to the cell marker called Prostate Stem Cell Antigen (PSCA), which is present on certain prostate, pancreatic and bladder cancers.
100 项与 124-iodine-labeled PSCA targeting minibody(University of California, Los Angeles) 相关的临床结果
100 项与 124-iodine-labeled PSCA targeting minibody(University of California, Los Angeles) 相关的转化医学
100 项与 124-iodine-labeled PSCA targeting minibody(University of California, Los Angeles) 相关的专利(医药)
100 项与 124-iodine-labeled PSCA targeting minibody(University of California, Los Angeles) 相关的药物交易